Rigel Pharmaceuticals RIGL Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $58.82M+10.3% | $69.8M+21.2% | $69.46M+25.6% | $101.69M+176% | $53.33M+80.6% | ||
| $4.61M+4.5% | $5.96M+2.9% | $4.75M-40.8% | $4.5M+60.5% | $4.41M+118% | ||
| $54.21M+10.8% | $63.85M+23.2% | $64.71M+36.9% | $97.18M+186% | $48.92M+77.8% | ||
| 92.2%+0.4pp | 91.5%+1.5pp | 93.2%+7.7pp | 95.6%+3.2pp | 91.7%-1.4pp | ||
| $11.68M+38.4% | $10.69M+89.7% | $7.35M+18.9% | $6.82M+23.1% | $8.44M+40.0% | ||
| $30.65M+10.6% | $29.99M+1.6% | $28.94M+7.0% | $29.26M+4.3% | $27.72M-2.6% | ||
| $46.93M+15.7% | $46.63M+13.9% | $41.04M-0.5% | $40.58M+11.5% | $40.56M+11.1% | ||
| $11.89M-7.0% | $23.17M+39.1% | $28.42M+102% | $61.1M+13,570% | $12.77M+283% | ||
| 20.2%-3.7pp | 33.2%+4.3pp | 40.9%+15.5pp | 60.1%+58.9pp | 23.9%+47.5pp | ||
| $1.43M-22.7% | $1.7M-13.1% | $1.89M-8.1% | $1.87M-7.6% | $1.85M-1.1% | ||
| $1.21M+104% | $1.24M+138% | $1.09M+157% | $753K+36.4% | $591K-0.3% | ||
| $11.66M+1.3% | $22.71M+49.2% | $27.62M+122% | $59.98M+5,923% | $11.51M+240% | ||
| $3M+4,520% | -$245.35M-27,949% | -$280K— | $369K— | $65K— | ||
| $8.65M-24.4% | $268.07M+1,769% | $27.9M+125% | $59.61M+5,888% | $11.45M+239% | ||
| 14.7%-6.7pp | 384%+359pp | 40.2%+17.7pp | 58.6%+61.4pp | 21.5%+49.4pp | ||
| $0.44-30.2% | $14.10+1,641% | $1.46+109% | $3.28+5,567% | $0.63+234% | ||
| $0.47-26.6% | $14.88+1,737% | $1.55+118% | $3.33+5,650% | $0.64+236% | ||
| 19.7M+8.3% | 18.8M+6.5% | 19.2M+8.5% | 18.2M+3.5% | 18.2M+3.7% | ||
| 18.4M+3.4% | 18M+2.3% | 18M+2.5% | 17.9M+1.9% | 17.8M+1.6% | ||
| $58.82M+10.3% | $69.8M+21.2% | $69.46M+25.6% | $101.69M+176% | $53.33M+80.6% | ||
| $11.89M-7.0% | $23.17M+39.1% | $28.42M+102% | $61.1M+13,570% | $12.77M+283% | ||
| $12.48M-6.7% | $23.77M+37.7% | $29.02M+97.9% | $61.71M+5,722% | $13.38M+304% | ||
| $12.48M-6.7% | $23.77M+37.7% | $29.02M+97.9% | $61.71M+5,722% | $13.38M+304% | ||
| 21.2%-3.9pp | 34.1%+4.1pp | 41.8%+15.3pp | 60.7%+57.8pp | 25.1%+47.3pp | ||
| $11.89M-7.0% | $23.17M+39.1% | $28.42M+102% | $61.1M+13,570% | $12.77M+283% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Rigel Pharmaceuticals's revenue?
- Rigel Pharmaceuticals (RIGL) generated $299.8M in revenue over the trailing twelve months, up 47.6% year over year.
- Is Rigel Pharmaceuticals profitable?
- Rigel Pharmaceuticals reported $364.2M in net income over the trailing twelve months, a 121.5% net margin.
- What are Rigel Pharmaceuticals's profit margins?
- Gross margin is 93.4% and operating margin is 41.6%, with a 121.5% net margin.
- What is Rigel Pharmaceuticals's earnings per share?
- Rigel Pharmaceuticals's diluted EPS over the trailing twelve months is $19.28.
- Where does Rigel Pharmaceuticals's income statement data come from?
- Every line is extracted from Rigel Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
